Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection (SEVO-COVID19)

Fundación para la Investigación del Hospital Clínico de Valencia

Status and phase

Terminated

Phase 4

Conditions

Acute Respiratory Distress Syndrome

COVID19 Infection

Treatments

Drug: Propofol

Drug: Sevoflurane

Study type

Interventional

Funder types

Other

Identifiers

SEVO-COVID19

Details and patient eligibility

About

It is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study.

Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours.

Patients will be randomized to one of the treatment groups:

SEV group: 25 patients with Sevoflurane sedation by inhalation, starting at 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved (BIS 40-50)
PRO group: 25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)

Enrollment

19 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Exclusion criteria

Intracranial hypertension
Hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients
Current volume < 250ml
History of malignant hyperthermia
Liver failure
Neutropenia (<0.5x109)
Pregnant or lactating women
Have received chemotherapy in the last month since their inclusion in the study